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Renal cell tumors (RCTs) are the most lethal of the common urological cancers. The widespread use of imaging 
entailed an increased detection of small renal masses, emphasizing the need for accurate distinction between benign 
and malignant RCTs, which is critical for adequate therapeutic management. Histone methylation has been implicated 
in renal tumorigenesis, but its potential clinical value as RCT biomarker remains mostly unexplored. Hence, the main 
goal of this study was to identify differentially expressed histone methyltransferases (HMTs) and histone demethylases 
(HDMs) that might prove useful for RCT diagnosis and prognostication, emphasizing the discrimination between 
oncocytoma (a benign tumor) and renal cell carcinoma (RCC), especially the chromophobe subtype (chRCC). We found 
that the expression levels of 3 genes—SMYD2, SETD3, and NO66—was significantly altered in a set of RCTs, which was 
further validated in a large independent cohort. Higher expression levels were found in RCTs compared to normal renal 
tissues (RNTs) and in chRCCs comparatively to oncocytomas. SMYD2 and SETD3 mRNA levels correlated with protein 
expression assessed by immunohistochemistry. SMYD2 transcript levels discriminated RCTs from RNT, with 82.1%
sensitivity and 100% specificity [area under curve (AUC) = 0.959], and distinguished chRCCs from oncocytomas, with 
71.0% sensitivity and 73.3% specificity (AUC D 0.784). Low expression levels of SMYD2, SETD3, and NO66 were 
significantly associated with shorter disease-specific and disease-free survival, especially in patients with non-organ 
confined tumors. We conclude that expression of selected HMTs and HDMs might constitute novel biomarkers to assist 
in RCT diagnosis and assessment of tumor aggressiveness.
Introduction
Kidney cancer is the most lethal of the common urological
cancers, with 337,860 new cases and 143,369 deaths registered
worldwide in 2012.1 In the United States, 63,920 new cases and
13,860 deaths due to kidney cancer were estimated in 2014.2
Renal cell tumors (RCTs), which originate from renal tubule
cells, are the most frequent kidney neoplasms, accounting for
85% to 90% of all cases.3 RCTs are a heterogeneous group of
neoplasms, comprising several different histological subtypes,
each with distinct morphologic, genetic, and clinical features.
The four major RCT subtypes include 3 malignant tumors [clear
cell renal cell carcinoma (ccRCC, the most common subtype,
75% of all RCT), papillary RCC (pRCC, 10% of all RCT), and
chromophobe RCC (chRCC, 5% of all RCT)] and a benign
tumor (renal oncocytoma), comprising 3 to 5% of all adult
RCT.3 Due to their different clinical aggressiveness, accurate
classification is required for appropriate patient management.
The widespread use of imaging techniques has increased the
detection of small renal masses, requiring novel tools for accurate
diagnosis. Currently, RCT diagnosis relies on histopathological
examination of biopsy or surgical specimens, a task that is chal-
lenging owing to the overlapping features of some tumor sub-
types. One of the most common diagnostic problems is the
differential diagnosis between renal oncocytoma and chRCC,
especially its eosinophilic variant.4,5 Although these tumors share
some morphologic and imagiological features, they are biologi-
cally distinct, as chRCCs constitute low-grade malignant neo-
plasms that sometimes behave aggressively and carry a risk of
recurrence and metastization, whereas oncocytomas are benign
tumors, that might be more conservatively managed.6 Among
RCC, prognostication is also a challenging task. Although patho-
logical stage, nuclear grade, histologic subtype and performance
status are commonly used in clinical practice,7 their ability to
accurately predict tumor behavior is limited.8,9
Epigenetic alterations, comprising aberrations in DNA
methylation patterns, deregulated chromatin machinery, and
non-coding RNAs expression, play a critical role in neoplastic
transformation, including renal carcinogenesis.10-12 The modu-
lation of chromatin conformation through covalent posttransla-
tional histone modifications is a fundamental mechanism of
gene transcription regulation, which includes methylation, acet-
ylation, phosphorylation, ubiquitylation, and sumoylation of
specific residues.13 Specifically, histone methylation, occurring
at the side chains of lysine or arginine residues, is a dynamic
process mediated by histone methyltransferases (HMTs) and
histone demethylases (HDMs). More than 50 HMTs and
HDMs have been identified thus
far and, unlike other histone
modifications, methylation does
not change the charged state of
the residues and, therefore, the
effect on gene expression is
dependent on the residue and its
methylation level (mono-, di-, or
tri-methylation).14,15 In RCTs,
the deregulation of chromatin
machinery has been increasingly
acknowledged as an important
mechanism of neoplastic trans-
formation (comprehensively
reviewed in16), highlighting its
potential role as diagnostic and
prognostic biomarker.
The main goal of this study
was to identify HMTs and
HDMs that might be used as
biomarkers to assist in diagnosis
and prognosis of RCT. For that
purpose, we screened 87 HMTs
and HDMs genes for differential
expression between normal renal
tissue and RCT, as well as
among RCT subtypes, with a
particular emphasis on the
discrimination of chRCC from
oncocytoma. Differentially
expressed genes were then vali-
dated in a large series of RCTs
and renal normal tissues (RNT).
Finally, its clinical usefulness as biomarkers was assessed and
compared with standard clinicopathological parameters.
Results
Screening of histone methyltransferases and demethylases
Globally, the analysis of 58 HMTs and 29 HDMs expression
levels in 5 chRCCs, 5 oncocytomas and 5 RNTs, disclosed
HMTs upregulation in RCTs compared to RNTs. Conversely,
HMTs and HDMs were generally downregulated in chRCCs
compared to oncocytomas (Fig. S1). However, only SMYD2
(PD 0.01), SETD3 (PD 0.005), and NO66 (PD 0.014) showed
significantly higher expression levels in RCTs compared to
RNTs, and were simultaneously overexpressed in chRCCs in
comparison to oncocytomas.
Validation of selected genes
Validation of SMYD2, SETD3 and NO66 by RT-qPCR in a
series of 160 RCTs and 10 RNTs confirmed that these 3 enzymes
were significantly overexpressed in RCTs compared to RNTs
(P < 0.001 for SMYD2 and SETD3, P D 0.001 for NO66;
Fig. 1A, 1-3). Additionally, expression levels of SETD3 and
Figure 1. Distribution of expression levels of selected genes. Comparison between RCTs and RNTs for SMYD2
(A1), SETD3 (A2), and NO66 (A3). Benign tumors versus malignant tumors for SMYD2 (B1), SETD3 (B2), and
NO66 (B3). Distribution of SMYD2 (C1), SETD3 (C2), and NO66 (C3) expression levels according to renal cell
tumor subtype. (**** P< 0.0001; *** P < 0.001; ** P < 0.01).
NO66 differed significantly between benign and malignant
RCTs (P D 0.003 and P D 0.001, respectively; Fig. 1B, 1-3).
Among the 4 RCT subtypes analyzed, chRCC displayed the
highest expression levels for the 3 genes, followed by oncocytoma
and then by pRCC and ccRCC (Fig. 1C, 1-3). Pairwise compari-
sons showed statistically significant differences of SMYD2,
SETD3, and NO66 expression, in chRCC vs. pRCC (P < 0.001,
P < 0.001, and P D 0.004, respectively) and chRCC vs. ccRCC
(P < 0.001 for all), as well as for SETD3 and NO66 expression
in oncocytoma vs. pRCC (P < 0.001 and P D 0.001, respec-
tively) and oncocytoma vs. ccRCC (P < 0.001 for both). Addi-
tionally, SMYD2 expression levels differed significantly
(P < 0.001) between chRCC vs. oncocytoma (Fig. 1C, 1-3), in
this validation series.
Correlation analysis for SMYD2, SETD3, and NO66 expres-
sion in RCC revealed that these 3 genes were significantly
co-expressed (SMYD2 – SETD3: r D 0.759; SMYD2 – NO66:
r D 0.639; SETD3 – NO66: r D 0.741; P < 0.001 for all).
Association between gene expression and clinicopathological
features
Clinical and pathological features of patients included in this
study are depicted in Table 1. No significant differences in gender
were apparent between RCT patients and controls (PD 0.524). In
RCTs, NO66 expression levels were significantly higher in females
(P D 0.044) and SMYD2 expression levels were associated with
patient’s age (PD 0.031). In malignant tumors, no statistically sig-
nificant associations were disclosed between SMYD2, SETD3, or
NO66 expression levels and pT (Table S1, Fig. S2), nor with path-
ological stage (P D 0.692, P D 0.724 and P D 0.843, respecti-
velly). SMYD2 and SETD3 expression levels were significantly
higher in Fuhrman grade 1/2 vs. 3/4 ccRCCs and pRCCs
(P D 0.045 and P D 0.021, respectively; Table S2, Fig. S3). Fuhr-
man grading was not applied to chRCCs because this grading sys-
tem does not reflect chRCC clinical aggressiveness and an
alternative grading system has been proposed.17
Diagnostic performance of selected genes
The diagnostic performance of SMYD2, SETD3, and NO66
mRNA expression was assessed in 3 different settings, using ROC
curve analysis: (i) identification of RCTs vs. renal normal tissue;
(ii) discrimination of malignant from benign RCTs; and (iii) dis-
tinction of chRCC from oncocytoma (Table 2). Whereas SMYD2
expression levels discriminated RCTs from normal kidney (80.6%
sensitivity, 100% specificity, AUC D 0.961; Table 2 and Fig. 2),
the performance of all 3 genes in distinction of malignant from
benign tumors was modest (highest AUC D 0.671, for NO66)
(Table 2). Finally, SMYD2 expression levels could distinguish
chRCCs from oncocytomas (AUC D 0.794) with 72.5% sensitiv-
ity and 72.5% specificity (Table 2).
Survival analysis
The median follow-up of RCC patients was 167 months (range:
1-391months).When considering the 7 years period defined for sur-
vival analysis, 10 patients died and 13 developed metastasis. Patients
with kidney-confined tumors (Stage I and Stage II) displayed a
Table 2. Validity estimates for each enzyme as a tissue biomarker
(%) SMYD2 (%) SETD3 (%) NO66 (%)
SE 80.6 85 65.63
SP 100 80 100
PPV 100 98.6 100
RCT vs. normal renal tissue NPV 24.4 25.0 15.4
Accuracy 81.8 84.7 67.6
AUC 96.1 83.6 81.7
SE 40.8 60.0 60.0
SP 65.0 65.0 67.5
PPV 77.8 83.7 84.7
RCC vs. oncocytoma NPV 26.8 35.1 36.0
Accuracy 46.9 61.3 61.9
AUC 54.2 66.0 67.1
SE 72.5 45.0 50.0
SP 72.5 85.0 57.5
PPV 72.5 75.0 54.1
chRCC vs.oncocytoma NPV 72.5 60.7 53.5
Accuracy 72.5 65.0 53.8
AUC 79.4 59.1 52.3
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative
predictive value; AUC, area under the curve; RCT, renal cell tumor; RCC, renal
cell carcinoma; chRCC: chromophobe RCC
Table 1. Clinical and pathological data of patients included in the present
study
Tumor Normal
Number of patients, n 160 10
Age, median (range) 61 (29-86) 67.5 (20-83)
Gender, n (%)
Male 92 (57.5) 7 (70.0)
Female 68 (42.5) 3 (30.0)
Histological subtype, n (%) n.a.
Clear cell RCC 40 (25.0)
Papillary RCC 40 (25.0)
Chromophobe RCC 40 (25.0)
Oncocytoma 40 (25.0)
pT, n (%) n.a.
pT1 68 (42.5)
pT2 23 (14.4)
pT3 29 (18.1)
pT4 0 (0.0)
n.a. (oncocytoma) 40 (25)
Pathological stage, n (%) n.a.
I 68 (42.5)
II 23 (14.4)
III 25(15.6)
IV 4 (2.5)
n.a. (oncocytoma) 40 (25)
Fuhrman grade, n (%) n.a.
1 3 (1.9)
2 41 (25.6)
3 58 (36.3)
4 18 (11.3)
n.a. 40 (25.0)
Metastasis, n (%) 13 (10.8) n.a.
Clear cell RCC 4 (30.8)
Papillary RCC 7 (53.8)
Chromophobe RCC 2 (15.4)
RCC, Renal Cell Carcinoma; n.a., not applicable
significantly higher disease-specific survival (DSS) (P < 0.001,
respectively); however, no statistically significant difference was
apparent for DFS (PD 0.055). DSS (PD 0.018), but not DFS, was
also significantly different among the 3 RCC subtypes. DSS and
DFS did not associate with age, gender, or Fuhrman grade for the 3
RCC subtypes in this series. However, considering only ccRCC
and pRCC, Fuhrman grade 4 was associated with lower DSS
(P< 0.001) andDFS (P< 0.001).
Focusing on the expression levels of the validated enzymes, sur-
vival analysis showed that low SMYD2, SETD3, and NO66
expression levels were significantly associated with shorter DSS
(P D 0.012, P D 0.001, and P D 0.011, respectively; Fig. 3A) and
DFS (P < 0.001, P < 0.001 and P D 0.001, respectively,
Fig. 3B). When evaluating each enzyme’s expression level and pT
stage in multivariate analysis (pT and SMYD2 expression level; pT
and SETD3 expression level; pT and NO66 expression level), low
levels of all 3 genes and pT3 were
significantly associated with
shorter DSS, and low SMYD2
expression levels and pT3 were
significantly associated with
shorter DFS (Table S3). Similar
results were depicted for patholog-
ical stage (pTNM; data not
shown). Conversely, in a model
comprising gender, histological
subtype, pathological stage,
SMYD2, SETD3, and NO66
expression levels simultaneously,
only patients with tumors not
confined to the kidney (Stage III /
Stage IV) and that presented metastasis during the follow-up were
found to have a significantly increased risk of death due to RCC.
Moreover, patients with lower SMYD2 expression levels and
tumors not confined to the kidney (Stage III / Stage IV) presented
a significantly increased risk of RCC progression (Table 3).
Immunohistochemical evaluation of SMYD2 and SETD3
expression
Immunoreactivity for SMYD2 and SETD3 was observed in the
cytoplasm. In normal renal parenchyma, weak to moderate
SMYD2 and SETD3 expression was found in tubular epithelial
cells. Oncocytomas and chRCC globally displayed higher staining
intensity and/or percentage of positive cells, compared to ccRCC
and pRCC, following the trend depicted for mRNA expression lev-
els. Indeed, a significant association was documented between
mRNA relative expression (RT-qPCR) and protein expression
(immunohistochemistry) classified
as high and low, both for SMYD2
(P D 0.002) and SETD3
(P D 0.008) (Fig. S4). However,
SMYD2 and SETD3 immunore-
activity was not associated with
Fuhrman grade (P D 0.403 and
PD 0.110, respectively) in ccRCC
and pRCC or with pathological
stage (P D 0.636 and P D 0.609,
respectively), DSS (P D 0.599 and
P D 0.3 respectively), and DFS
(P D 0.99 and P D 0.192, respec-
tively) in RCC.
RNA expression and survival
analysis of renal cell carcinoma
patients from TCGA
Further validation of the results
depicted for SMYD2, SETD3 and
NO66 expression was performed
in a larger and independent data-
set from TCGA, including RNA-
seq expression data from 889
RCC patients (533 ccRCC, 290
Figure 2. Receiver operator characteristic (ROC) curves evaluating performance of SMYD2 (A), SETD3 (B), and
NO66 (C) expression levels as biomarkers for discrimination between RCTs and RNTs (AUC: area under the
curve).
Figure 3. Kaplan-Meier with log-rank test estimates of disease-specific survival in 62 RCC patients according
to expression levels of SMYD2 (A1), SETD3 (A2), and NO66 (A3); and of disease-free survival in 88 RCC patients
according to expression levels of SMYD2 (B1), SETD3 (B2) and NO66 (B3). The results of RT-qPCR presented
were categorized using first quartile (25th percentile) value as cutoff.
pRCC, and 66 chRCC) and 129 matched normal samples (n D
72, n D 32, and n D 25, respectively; Table S4). SMYD2 expres-
sion was significantly higher (P < 0.0001), and SETD3 expression
significantly lower (P < 0.0001), in RCC than in matched normal
samples, whereas no statistically significant difference was disclosed
for NO66 expression (Fig. 4A). Similarly to the results found in
our series, for all 3 genes, statisti-
cally significant higher expression
levels were found in chRCC com-
pared to pRCC and ccRCC
(Fig. 4B). Correlation analysis for
SMYD2, SETD3, and NO66
expression showed that SMYD2
was significantly co-expressed with
SETD3 (r D 0.24, P < 0.0001)
and SETD3 with NO66 (r D 0.28,
P< 0.0001) in RCTs.
SETD3 and NO66 expression
levels were significantly lower
(P < 0.0001 and P D 0.045,
respectively) in pT1/pT2 vs. pT3
RCCs, whereas no statistically sig-
nificant difference was observed
for SMYD2 (Fig. S5). Conversely,
lower grade (Fuhrman grade 1/2)
ccRCC also displayed a signifi-
cantly higher SETD3 expression
than tumors with higher grade
(Fuhrman 3/4; Fig. S6).
Table 3. Prognostic factors for Renal Cell Carcinoma obtained by Cox regression analysis
Prognostic Factor Univariate Analysis Multivariate Analysis
HR 95% CI for HR P value1 HR 95% CI for HR P value1
Disease Specific Survival
Pathological Stagex 7.905 2.043-30.585 0.003 4.937 1.255-19.428 0.022
Metastasis (during follow-up)f 35.88 7.599-169.36 <0.001 27.378 5.702-131.459 <0.001
SMYD2 expression level* 4.43 1.25-15.73 0.021 0.614
SETD3 expression level* 7.02 1.81-27.21 0.005 0.819
NO66 expression level* 4.50 1.27-15.99 0.02 0.705
Histological Subtyped
chRCC — — 0.046 0.407
pRCC 7.6 0.94-61.85 0.058 0.180
ccRCC 1.66 0.149-18.343 0.681 0281
Genderc 0.231 0.680
Disease Free Survival
Pathological Stagex 2.81 0.94-8.38 0.064 3.31 1.105-9.887 0.032
SMYD2 expression level* 7.58 2.33-24.66 0.001 8.30 2.543-27.117 <0.001
SETD3 expression level* 7.53 2.32-24.51 0.001 0063
NO66 expression level* 5.30 1.73-16.23 0.003 0.233
Histological Subtyped
chRCC — — 0.144 0.273
pRCC 3.97 0.82-19.13 0.086 0.118
ccRCC 1.63 0.30-8.95 0.575 0.152
Genderc 0.238 0.965
HR: Hazard Ratio; CI: Confidence Interval, n.s.: not significant.
1Cox regression p value; significant when P < 0.05.
xStage I / Stage II vs Stage III / Stage IV; reference group: Stage I / Stage II.
*Reference group: high expression level.
dchRCC: chromophobe Renal Cell Carcinoma vs. pRCC: papillary Renal Cell Carcinoma vs. ccRCC: clear cell Renal Cell Carcinoma; Reference group: chRCC.
fReference group: Absence of metastasis.
cReference group: Male
Figure 4. Distribution of expression levels of selected genes from the TCGA data set (http://tcga-data.nci.nih.
gov/tcga/dataAccessMatrix.htm. Accessed 2015). Comparison between RCCs and RNTs for SMYD2 (A1),
SETD3 (A2), and NO66 (A3). Distribution of SMYD2 (B1), SETD3 (B2), and NO66 (B3) expression levels according
to renal cell carcinoma subtype. (**** P < 0.0001; *** P < 0.001; ** P< 0.01).
The median follow-up of RCC patients from TCGA was 29.4
months (range: 0-195 months), in which 212 patients died and
92 developed metastasis. A significantly higher risk of death due
to RCC was detected in ccRCC patients with non-organ con-
fined tumors (Stage III and Stage IV), lower SETD3 expression,
that developed metastasis during follow-up and with ccRCC and
pRCC (compared to chRCC), in multivariate analysis
(P < 0.0001; Table 4). Interestingly, Stage III / Stage IV tumors
and lower NO66 expression levels associated with shorter time to
disease progression in multivariate analysis (P < 0.001 and
P D 0.018, respectively) (Table 4).
When analyzing each subtype separately, multivariate analysis
revealed that Stage III / Stage IV was associated with shorter DSS
in all subtypes and shorter DFS in ccRCC and pRCC; occur-
rence of metastasis during follow-up with shorter DSS in ccRCC
and pRCC; low SETD3 expression levels with shorter DSS in
ccRCC and pRCC and with shorter DFS in pRCC; and low
NO66 expression levels with shorter DSS in pRCC (Table S5).
DFS analysis was not performed to chRCC due to insufficient
available data in the TGCA database.
Discussion
The incidental diagnosis of small renal masses has increased in
recent years, and current imaging techniques, even when
complemented with biopsy, are limited in discriminating benign
from malignant entities, leading to surgical intervention in cases in
which it might be spared and the patient be managed conserva-
tively. Epigenetic-based biomarkers, including histone posttransla-
tional modifications and chromatin modulators, hold the promise
to assist in diagnosis through the discrimination between normal
and neoplastic tissue or between benign and malignant tumors,
helping in prognostication and stratifying patients according to risk
of disease progression. Evidence of widespread deregulation of
chromatin status in RCTs has been accumulating, and several
defects in epigenetic enzymes, including those responsible for chro-
matin packaging, histone modifications, and chromatin remodel-
ing, have been reported.18,19
In this study, we focused on altered histone methylation patterns
and screened the expression of HMTs and HDMs genes in RNT,
oncocytomas and chRCCs to determine whether their expression
levels might be used as diagnostic biomarkers to discriminate nor-
mal from neoplastic renal tissue, as well as benign (oncocytoma)
from malignant RCTs (especially chRCC). For most of the genes
assessed, differences in expression levels between normal and neo-
plastic samples were in line with previous reports on their role in
cancer. Thus, SETD2, a putative tumor suppressor in ccRCC,20
was mostly downregulated in RCT compared to RNTS, and a sim-
ilar trend was apparent for KDM5C, also reported to have a tumor
suppressive effect.21 KDM6A, previously reported to be overex-
pressed in RCTs,22 was found to be the second most upregulated
Table 4. Prognostic factors for TCGA dataset (http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm. Accessed 2014) by Cox regression analysis
Prognostic Factor Univariate Analysis Multivariate Analysis
HR 95% CI for HR P value1 HR 95% CI for HR P value1
Disease Specific Survival
Pathological Stagex 4.81 3.61-6.42 <0.0001 3.00 2.14-4.22 <0.0001
Metastasis (during follow-up) 6.14 4.59-8.20 <0.0001 2.62 1.86-3.70 <0.0001
SMYD2 expression level* 0.143 0.159
SETD3 expression level* 2.58 1.95-3.40 <0.0001 1.85 1.39-2.46 <0.0001
NO66 expression level* 0.220 0.850
Histological Subtyped
chRCC — — <0.0001 — — 0.047
pRCC 1.97 0.97-4.01 0.063 2.54 1.06-6.12 0.037
ccRCC 3.48 1.83-6.61 <0.0001 2.83 1.24-6.48 0.014
Genderc 0.625 0.196
Disease Free Survival
Pathological Stagex 5.79 2.23-15.00 <0.0001 7.51 2.77-20.37 <0.0001
SMYD2 expression level* 0.809 0.751
SETD3 expression level* 3.91 1.48-10.36 0.006 0.100
NO66 expression level* 4.42 1.62-12.06 0.004 4.74 1.30-17.26 0.018
Histological Subtyped
chRCC — — 0.882 0.707
pRCC 1.4e5 0-7.5e108 0.923 0.921
ccRCC 1.8e5 0-9.7e108 0.921 0.925
Genderc 0.972 0.449
HR: Hazard Ratio; CI: Confidence Interval, n.s.: not significant.
1Cox regression p value; significant when P < 0.05.
xStage I / Stage II vs Stage III / Stage IV; reference group: Stage I / Stage II.
*Reference group: high expression level.
dchRCC: chromophobe Renal Cell Carcinoma vs. pRCC: papillary Renal Cell Carcinoma vs. ccRCC: clear cell Renal Cell Carcinoma; Reference group: chRCC.
fReference group: Absence of metastasis.
cReference group: Male
gene in RCTs in our analysis. A divergent behavior was, however,
observed for EZH2, previously shown to be upregulated in ccRCCs
compared to adjacent normal tissues,22,23 whereas we found EZH2
downregulation in RCTs. Notwithstanding this latter result, which
might be due to the small number of cases or the main histological
subtype (chRCC) used for array analysis in our study, and/or the
use of adjacent morphologically normal renal tissue as control
(which we have found to harbor epigenetic alterations24) in the
aforementioned studies, the overall results of the array and the
agreement found for the 3 genes validated in a series of 160 primary
tumors, as well as in GEO database (http://www.ncbi.nlm.nih.gov/
gds) published array data,25 argue in favor of the validity of our
strategy for discovery of HDMs and HMTs as RCT biomarkers.
We found that 2 histone methyltransferases, SMYD2 and
SETD3, and a histone demethylase, NO66,14 were significantly
upregulated in RCTs compared to RNTs, and in chRCC com-
pared to oncocytoma, in the screening array. SMYD2 targets
lysines 4 and 36 of histone H3, as well as non-histone proteins
including p53, RB1, HSP90, and PARP-1.26-34 It plays an
important role in muscle function, mediating the methylation of
Hsp90, which stabilizes the sarcomeric region,29 and in the early
stages of embryonic differentiation.35 In cancer, SMYD2 is over-
expressed in bladder cancer36 and leukemia,37 as well as in esoph-
ageal squamous cell carcinoma and gastric carcinoma.38,39
SETD3, which also methylates lysines 4 and 36 of histone H3,
promotes differentiation of muscle cells40 and is overexpressed in
lymphomas, displaying oncogenic potential.41 NO66, which spe-
cifically targets lysines 4 and 36 of histone H3,42 is involved in
bone differentiation (osteoblast differentiation and bone forma-
tion),43 inducing chromatin repression through histone demeth-
ylation during osteoblast differentiation.44
Our screening data are in line with “GEO Data sets” publi-
cally available expression array data (http://www.ncbi.nlm.nih.
gov/gds) of 18 cases, comprising 9 chRCC and 9 oncocytomas,25
which also revealed a higher expression of SMYD2, SETD3, and
NO66 in chRCC compared to oncocytoma (Table S6). Impor-
tantly, this pattern of expression was also retained in our valida-
tion series: chRCC and oncocytoma displayed higher expression
levels than ccRCC and pRCC. This finding might denote the
common cellular origin of ccRCC and pRCC, on the one hand,
and of chRCC and oncocytoma, on the other, as previously sug-
gested.45 Indeed, expression levels of these 3 enzymes were signif-
icantly different between chRCC and pRCC, as well as between
chRCC and ccRCC, both in our validation series and in the
TCGA database. Additionally, SMYD2 expression levels differed
significantly between chRCCs and oncocytomas, indicating a
potential for discriminating among these 2 RCT subtypes, which
frequently display overlapping and confounding morphological
features that might impair differential diagnosis, especially in
small biopsies. Importantly, mutational analysis data accessible
in the COSMIC database (http://cancer.sanger.ac.uk/cosmic)46
revealed that, in RCC, SMYD2, and SETD3 mutations are
exceedingly rare [mutation rate of 0.22% (3/1345) and 0.32%
(4/1253), respectively] and were not reported for NO66. Thus, it
seems unlikely that the differences in gene expression we observed
might be due to genetic alterations.
We also found significantly higher expression levels of
SMYD2, SETD3, and NO66 in RCTs than in RNTs in the vali-
dation series. These results are similar to those observed in the
TCGA dataset for SMYD2 expression, keeping in mind that in
our validation series the normal tissue was collected from non-
RCT patients, whereas in TCGA database morphologically
matched normal renal tissue from RCC patients was analyzed.
This difference in normal samples may account for the higher
SETD3 expression in normal tissue than in RCC noted in the
TCGA data set. Moreover, among the 3 validated genes, SMYD2
expression levels also displayed the best diagnostic performance
for distinction between RCTs and normal renal tissue, thus
increasing the spectrum of scenarios in which it may assist in
diagnosis and classification of suspicious renal lesions. When
compared to other molecular techniques, FISH was reported to
allow the identification of RCT subtypes,47 specially to distin-
guish chRCC from oncocytoma,48 but the overlapping genetic
alterations mainly between chRCC and oncocytoma might ham-
per differential diagnosis.49 A molecular algorithm based on
qPCR gene expression correctly identified the RCC subtype in
83.3% of cases,50 and CGH allowed for the correct diagnosis in
93.5% of ccRCC, 100% of pRCC, 61.5% of chRCC, and
14.3% of oncocytomas,51 although in both studies less than 80
cases were analyzed.
Interestingly, SMYD2 and SETD3 differential expression at
transcript level was also apparent at protein level, as assessed by
immunohistochemistry, and a statistically significant correlation
between the 2 parameters was found. However, the wide varia-
tion in immunoexpression within RCT subtype and across sub-
types precludes its use as an ancillary tool for histopathological
evaluation. Notwithstanding, owing to the increasing availability
and use of molecular techniques in diagnostic pathology, the
assessment of mRNA expression in tissue samples or in fine-nee-
dle aspirates of suspicious lesions is within the reach of many
molecular pathology laboratories.
Besides its potential role as diagnostic biomarkers, we aimed
also at characterizing the prognostic value of HMTs and HDMs
expression in RCCs. Interestingly, low SMYD2, SETD3, and
NO66 expression levels associated with worse disease-specific sur-
vival and disease-free survival, in univariate analysis. The prog-
nostic value of SMYD2 overexpression has been reported in
leukemia,37,38 esophageal squamous cell carcinoma,37,38 and gas-
tric carcinoma,39 contrarily to our findings in RCC. Besides dif-
ferences in tumor model, it should be emphasized that survival
analyses in our series were mostly influenced by pRCC and
ccRCC, which displayed the lowest expression levels for the 3 val-
idated genes, and that are acknowledged as the most aggressive
RCC subtypes. Furthermore, in multivariate analysis assessing
the expression level of each gene, pT, histological subtype, and
gender, statistical significance was retained for pT and expression
level for the 3 enzymes, both for DSS and DFS, with low expres-
sion level and pT3 associating with worse prognosis, thus indicat-
ing that each gene independently adds prognostic information to
pT stage. When combining the expression levels of the 3 genes
with pathological stage, occurrence of metastasis during follow-
up, histological subtype, and gender, for our series and for the
TCGA dataset separately, Stage III / Stage IV and the develop-
ment of metastasis associated with shorter DSS in both cohorts.
Furthermore, low SETD3 expression and ccRCC and pRCC
(compared to chRCC) subtypes also associated with decreased
DSS, but only in the TCGA data set. A shorter DFS was associ-
ated with low SMYD2 expression levels and Stage III / Stage IV
in our series, and low NO66 and Stage III / Stage IV in the
TCGA dataset. These differences might be due to (i) cohort size,
(ii) dissimilar proportions of the 3 histological subtypes in the 2
cohorts, or (iii) differences in period of follow-up. Since the
number of events, both cancer-specific deaths and development
of metastasis, were scarce in our series, mainly in the ccRCC
(subtypes 2 and 4, respectively) and chRCC (subtypes 1 and 2,
respectively), survival analysis was not performed separately for
each subtype. To overcome this limitation, TCGA data set was
further explored. Interestingly, when analyzing each subtype sep-
arately in multivariate analysis, SETD3 was associated with
shorter DSS in ccRCC and shorter DSS and DFS in pRCC,
underlining the potential clinical value of SETD3 as a prognostic
biomarker.
To the best of our knowledge, only a few studies have
addressed the role of SMYD2, SETD3, and NO66 in tumorigen-
esis, as previously described, although none has included RCTs.
The knowledge of the specific role of SMYD2, SETD3, and
NO66 in renal carcinogenesis, uncovering the participation of
these enzymes in the neoplastic transformation of renal epithe-
lium and in RCC progression, might additionally provide a
stronger biological rational for its use as clinically useful diagnos-
tic and prognostic biomarkers.
Patients and Methods
Patients and sample collection
A total of 160 RCTs, comprising ccRCCs, pRCCs, chRCCs,
and oncocytomas (40 cases of each type), were prospectively col-
lected from patients consecutively diagnosed and submitted to
nephrectomy at the Portuguese Oncology Institute – Porto,
between 2001 and 2014. As controls, 10 renal normal tissue
(RNT) samples were collected from morphologic normal kidneys
of patients subjected to nephrectomy due to upper urinary tract
urothelial carcinoma. All specimens were immediately frozen
after surgery and stored at ¡80C. Sampling of more than 70%
of malignant cell was confirmed by 2 slides stained with hema-
toxylin and eosin (H&E) taken before and after frozen section
collection for RNA extraction. Routine histological slides from
formalin-fixed paraffin-embedded (FFPE) tissue of the same sur-
gical specimens were assessed for diagnosis, TNM staging, and
Fuhrman grading. Relevant clinical data was also collected from
clinical charts. This study was approved by the Institutional
Review Board of Portuguese Oncology Institute – Porto [Com-
iss~ao de Etica para a Saude-(CES-IPOFG-EPE 518/10)].
RNA extraction
Samples were suspended in TRIzol reagent (InvitrogenTM,
Cat.#15596018) and chloroform (Merk Millipore, Cat.
#MCX10601) was added to the lysed cells. Total RNA was puri-
fied using the Ambion PureLink RNA Mini Kit (InvitrogenTM,
Cat.#12183025), according to manufacturer recommendations.
RNA concentrations and purity ratios were determined using a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies) and RNA quality was verified by electrophoresis.
Screening of histone methyltransferases and demethylases
A total of 10 RCT (5 oncocytomas and 5 chRCCs) and 5
RNT samples were treated with Ambion TURBO DNA-freeTM
kit (Invitrogen, Cat.#1907) to remove any DNA contamination,
and then 1 mg of total RNA was reversely transcribed using the
High Capacity cDNA Reverse Transcription kit (Applied Bio-
systems, Cat.#4368814) according to manufacturer instruc-
tions. Expression of histone methylation enzymes (58 HMTs
and 29 HDMs), was assessed by RT-qPCR using custom made
TaqMan Array 96-Well expression Plates (Applied Bio-
systems, Cat.#4391528) in an ABI-7500 Real-Time PCR sys-
tem (Applied Biosystems, Cat.#4351105).
Each gene was run in triplicate and the amount of mRNA was
normalized to Glucuronidase b (GUSb) and Human 18S rRNA
(18S) reference genes. Comparative CT method was used to
determine the fold-difference in gene expression between RNT
and RCT, as well as between chRCC and oncocytoma. Genes
that reached statistically significant differences in expression levels
between these groups, and displayed higher or lower expression
levels in RCT vs. RNT or in chRCC vs. oncocytoma, were
selected for further analysis.
Validation of selected enzymes
Candidate genes’ mRNA levels were evaluated in a larger
series of 160 RCTs, including 40 ccRCCs, 40 pRCCs, 40
chRCCs, 40 oncocytomas, and 10 RNTs. A total of 300ng was
reversely transcribed and amplified using TransPlexWhole
Transcriptome Amplification Kit (Sigma-Aldrich, Cat.
#WTA1) purified with QIAquick PCR Purification Kit (QIA-
GEN, Cat.#28106), and mRNA levels were evaluated using
TaqMan Gene Expression Assays [Applied Biosystems, Cat.#
Hs00220210 m1 (SMYD2), Hs00260120 m1 (SETD3),
Hs02743012 s1 (NO66), Hs99999908 m1 (GUSB),
Hs99999901 s1 (18s)], according to manufacturer’s instructions.
For each sample, expression levels were normalized using 2 inter-
nal reference genes, GUSb and 18S, according to the formula:
target gene relative expression D target gene expression level /
[(GUSb expression level C 18S expression level) / 2]. Each plate
included multiple non-template controls and serial dilutions of a
cDNA Human Reference Total RNA (Agilent Technologies,
Cat.#750500) to construct a standard curve.
Immunohistochemistry
A representative slide from 120 RCT cases of the validation
cohort (30 cases available from each subtype) was selected and
4 mm sections from FFPE tissue were obtained. Briefly, after depar-
affinization antigen retrieval was performed by heating
(20 min) in an antigen unmasking solution (Vector Laboratories,
Cat.#H3300), endogenous peroxidase activity was neutralized with
0.6% hydrogen peroxide (Merk Millipore, Cat.#107298) for 20
minutes. Then, protein detection was performed using the Novo-
linkTMMax Polymer Detection System (Leica Biosystems, Cat.
#RE7260-K), according to manufacturer instructions. Slides were
incubated in a humid chamber with rabbit polyclonal antibodies,
specific for SET and MYND domain containing 2 (SMYD2)
(Sigma Aldrich, Cat.#HPA029023) in a 1:250 dilution (4C,
overnight) and specific for SET domain containing 3 (SETD3)
(Novus Biologicals, Cat.#NBP-88416) in a 1:200 dilution (room
temperature, 1 hr). For NO66 several primary antibodies were
tested but none was found to provide reliable results.
All washings were performed with Tris buffered saline with
Tween 20 (TBS-T) (Sigma-Aldrich, Cat.#T9039). To unveil
antigen-antibody binding reaction, slides were incubated for 7
minutes, in the dark, in a 0.05% (m/v) 3, 30-diaminobenzidine
(DAB) solution (Sigma-Aldrich, Cat.#D7304) in phosphate-
buffered saline (PBS) (Biochrom Ltd., Cat.#L1835). Then, slides
were counterstained with hematoxylin (Merck Millipore, Cat.
#105174), dehydrated and diaphanized.
Slides were evaluated by 2 pathologists for SMYD2 and
SETD3 immunoexpression and classified using a semi-quantita-
tive scale for both staining intensity (0 – no staining; 1 – intensity
lower than normal kidney; 2 – intensity equal to normal kidney;
3 – intensity higher than normal kidney) and percentage of posi-
tive cells (0 – < 10%; 1 – 10-33%; 2 – 33-67%; 3 – >67%), in
each tumor. Staining intensity and percentage of positive cell
scores were combined (Score S D staining intensity x percentage
of positive cells) to assign a composite score in each tumor, which
was then stratified into low expression (S < 4) and high expres-
sion (S  4) groups, which basically correspond to RCTs with
less than 33% stained cells or staining intensity lower than nor-
mal kidney, and RCTs with at least 33% stained cells with an
intensity equal or higher than normal kidney.
TCGA dataset analysis in renal cell carcinoma patients
The Cancer Genome Atlas (TCGA) was used to obtain data
on SMYD2, SETD3 and NO66 expression and clinical informa-
tion, when available, from renal cell carcinoma patients and
matched normal tissue samples.52 All expression data from sam-
ples hybridized by the University of North Carolina, Lineberger
Comprehensive Cancer Center, using Illumina HiSeq 2000
RNA Sequencing version 2 analysis, were downloaded from
TCGA data matrix (http://tcga-data.nci.nih.gov/tcga/tcgaDown-
load.jsp).52 This data set included 533 ccRCC and 72 matched
normal patient samples, 290 pRCC and 32 matched normal
patient samples, and 66 chRCC and 25 matched normal patient
samples. To prevent duplicates, when there was more than one
portion per patient, median values were used. The provided value
was pre-processed and normalized according to “level 3” specifi-
cations of TCGA (see http://cancergenome.nih.gov/dataportal/
for details). Clinical data of each patient was provided by the Bio-
specimen Core Resources (BCRs). This data is available for
download through TCGA data matrix (http://tcga-data.nci.nih.
gov/tcga/dataAccessMatrix.htm).52
Statistical analysis
Chi-square, Fisher’s exact test and, non-parametric tests were
used to ascertain the statistical significance of differences among
groups of samples, namely Kruskal-Wallis test (KW) for multiple
comparisons and Mann-Whitney U test (MW) for pair-wise
comparisons, as appropriate. Spearman’s test was carried out to
ascertain correlations between age and HMTs or HDMs expres-
sion levels, as well as between HMTs and HDMs mRNA expres-
sion levels.
Receiver operator characteristics (ROC) curves were con-
structed to assess the diagnostic performance of biomarkers,
by plotting the true positive rate (sensitivity) against the false
positive rate (1-specificity), and the area under the curve
(AUC) was calculated. Sensitivity, specificity, positive and
negative predictive values, and accuracy were calculated based
on cutoff values based on ROC curve analysis, prioritizing
specificity and then sensitivity.
For survival analysis, a 7-year follow-up time was consid-
ered, both for disease-specific survival (DSS) and disease free
survival (DFS), as patient recruitment occurred during
13 years. Prognostic significance of standard clinicopathologi-
cal variables (histological subtype, pathological stage, Fuhrman
grade, age, gender) and as well as of HMTs and HDMs
expression levels, was assessed by constructing disease-specific
and disease-free survival curves using the Kaplan-Meier
method, with log-rank test and Cox-regression analysis for
each variable (univariate test). For this purpose, expression lev-
els of SMYD2, SETD3, and NO66 were classified as low or
high based on the 25th percentile expression value of each
gene. Similarly, SMYD2 and SETD3 immunoreactivity was
classified as low or high according to Score S. A Cox-regres-
sion model using Forward Stepwise (conditional) test compris-
ing the different variables (multivariate test) was also
performed, including the 160 RCC patients, both for disease-
specific (DSS) and disease-free (DFS) survival. A similar Cox-
regression analysis (univariate and multivariate) was performed
for patients from the TCGA dataset, and expression levels
were classified as low or high based on the 25th percentile
expression value of each gene, too.
Statistical significance was set at P < 0.05. Bonferroni’s cor-
rection was applied for pairwise comparisons following multiple
groups’ analyses. Statistical analysis was performed using SPSS
software for Windows, version 22.0 (IBM-SPSS Inc.), and graphs
were built using GraphPad Prism 6.0 software for Windows
(GraphPad Software Inc.).
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